All this means that Viking is a great biotech buy -- its candidate is promising, you can benefit from getting in on the dip, and momentum has been picking up. But you don't have to rush to scoop up ...

Clinical trial sites often open and close rapidly, with 60% ceasing operations within the first year, impacting patient ...

OPERA-02: a phase 3 randomized, double-blind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+, HER2- advanced breast cancer ...

Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted ...

Trials-in-progress poster of ongoing pivotal Phase 3 trial of DNA-mediated immunotherapy accepted at both IGCS and ESMO Congress ...

Asian patients with non-cystic fibrosis bronchiectasis had a lower annualized exacerbation rate and less lung function ...

A recent trial evaluates the impact of dostarlimab on ovarian cancer treatment, revealing modest benefits and no significant safety concerns with niraparib.

MDX2004 is designed to activate T cells through three unique signalling pathways to enhance immune activation.

UCSF researchers and clinicians presented innovative research and treatment strategies at the American Society of Radiation Oncology’s 2025 Annual Meeting in San Francisco, which ran from Sept. 27 to ...

The FDA has granted fast track designation to JSKN003, a biparatopic HER2-targeting antibody-drug conjugate (ADC), for the ...